This article is more than 5 years old. Information may no longer be current.

Spark Therapeutics reports $2.3 million in revenue in first quarter

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Spark Therapeutics, developer of SPK-RPE65, a potential gene therapy treatment for RPE65-mediated inherited retinal degenerations, reported $2.3 million in revenue in the first quarter of 2015 compared with $20,000 in the same quarter of 2014. The company recognized $1.3 million of revenue associated with a collaboration with Pfizer, according to a press release.

Net loss was reported at $10.4 million, or $0.58 per common share, in the first quarter compared with $4.4 million, or $0.86 per common share, in the same quarter in 2014.

Research and development expenses were reported at $8.3 million in the first quarter compared with $3.4 million in the same quarter in 2014.